Literature DB >> 2976898

Effects of 8-OH-DPAT on ultrasonic vocalization and audiogenic immobility reaction in pre-weanling rats.

E Hård1, J Engel.   

Abstract

Emotional reactivity in preweanling rats was assessed by observations of two reactions characteristic for two different age periods, respectively. One reaction, ultrasonic vocalization in rat pups separated from mother and littermates, was observed during early postnatal age (10 days). The other reaction, rigid immobility elicited by a sudden sound, was observed at the age of weaning (20 days). Previous studies from this laboratory indicated that the serotonergic system was involved in the control of both of these reactions. In the present study this notion was further tested by investigating the effects on these reactions of the congener of ergot 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), characterized as a centrally-acting, potent and selective agonist of 5-hydroxytryptamine (5-HT). Rat pups, 10 days of age, were treated subcutaneously with 7.5, 15 and 30 micrograms/kg of 8-OH-DPAT and subsequently tested for ultrasonic vocalization. Animals, 20 days old, were treated with 15, 30 and 60 micrograms/kg of 8-OH-DPAT before testing of the immobility reaction. The results showed a dose-dependent decrease of the amount of ultrasonic vocalization and of the duration of the immobility reaction, indicating an anxiolytic-like action of 8-OH-DPAT in both behavioural patterns. A possible explanation for the antagonistic effect of 8-OH-DPAT is that this drug exerts a preferential agonistic effect on presynaptic (auto-) 5-HT receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2976898     DOI: 10.1016/0028-3908(88)90056-1

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

Review 1.  Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics.

Authors:  K A Miczek; E M Weerts; J A Vivian; H M Barros
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

2.  Role of maternal 5-HT(1A) receptor in programming offspring emotional and physical development.

Authors:  A van Velzen; M Toth
Journal:  Genes Brain Behav       Date:  2010-11       Impact factor: 3.449

3.  Diazepam and gepirone selectively attenuate either 20-32 or 32-64 kHz ultrasonic vocalizations during aggressive encounters.

Authors:  J A Vivian; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Developmental rodent models of fear and anxiety: from neurobiology to pharmacology.

Authors:  Despina E Ganella; Jee Hyun Kim
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Difluoromethylornithine (DFMO) reduces deficits in isolation-induced ultrasonic vocalizations and balance following neonatal ethanol exposure in rats.

Authors:  Maribel A Rubin; Kristen A Wellmann; Ben Lewis; Ben J Overgaauw; John M Littleton; Susan Barron
Journal:  Pharmacol Biochem Behav       Date:  2008-10-25       Impact factor: 3.533

6.  Comparison between cholinergically and naturally induced ultrasonic vocalization in the rat.

Authors:  S M Brudzynski; D Ociepa; F Bihari
Journal:  J Psychiatry Neurosci       Date:  1991-11       Impact factor: 6.186

7.  Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists.

Authors:  J T Winslow; T R Insel
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Diazepam withdrawal: effects of diazepam and gepirone on acoustic startle-induced 22 kHz ultrasonic vocalizations.

Authors:  J A Vivian; W J Farrell; S B Sapperstein; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

9.  Reduced isolation-induced pup ultrasonic communication in mouse pups lacking brain serotonin.

Authors:  Valentina Mosienko; Daniel Beis; Natalia Alenina; Markus Wöhr
Journal:  Mol Autism       Date:  2015-03-08       Impact factor: 7.509

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.